Sort
16,300 grants matching “fatty liver disease”
Insulin Receptor Substrates and Insulin Action
$555,059C Ronald Kahn · Joslin Diabetes Center · R01 · FY2016 · DK
Insulin Receptor Substrates and Insulin Action
$555,059C Ronald Kahn · Joslin Diabetes Center · R01 · FY2015 · DK
Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)
$554,982Juan M. Pascual · Ut Southwestern Medical Center · R01 · FY2020 · NS
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
$554,963Kenneth Cusi · University Of Florida · R01 · FY2022 · DK
HCC Risk Stratification in MAFLD Cirrhosis
$554,835Hashem B El-Serag · Baylor College Of Medicine · P01 · FY2025 · CA
MAF1 Function and Metabolic Inefficiency
$554,600Ian M Willis · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · GM
Immunopathogenesis of non-alcoholic fatty liver disease
$554,436Senad Divanovic · Cincinnati Childrens Hosp Med Ctr · R01 · FY2022 · DK
Immunopathogenesis of non-alcoholic fatty liver disease
$554,436Senad Divanovic · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · DK
Immunopathogenesis of non-alcoholic fatty liver disease
$554,436Senad Divanovic · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · DK
Immunopathogenesis of non-alcoholic fatty liver disease
$554,436Senad Divanovic · Cincinnati Childrens Hosp Med Ctr · R01 · FY2023 · DK
Impaired VLDL secretion in progression of NAFLD and NASH in mice and humans
$554,435Nicholas Davidson · Washington University · R01 · FY2025 · DK
PQB-3: Discovery and validation of the driving mediators of cancer cachexia
$554,405Todd R. Golub · Broad Institute, Inc. · R01 · FY2014 · CA
Genetic and Metabolic Basis of Familial Lipodystrophies
$554,390Abhimanyu Garg · Ut Southwestern Medical Center · R01 · FY2017 · DK
Long-lived mice and species as test beds for drug and pathway discovery
$554,376Richard A. Miller · California Pacific Med Ctr Res Institute · U19 · FY2018 · AG
Allosteric regulation of SIRT1 by a PACS-2 and DBC1 regulatory hub
$554,136Angela M. Gronenborn · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · DK
Epigenetic markers of severity in nonalcoholic fatty liver disease
$553,850Johanna K Distefano · Translational Genomics Research Inst · R01 · FY2020 · DK
Exploring the Fetal Origins Hypothesis in Diverse Youth
$553,837Dana Dabelea · University Of Colorado Denver · R01 · FY2015 · DK
Lipid storage and utilization in physiology and obesity
$553,800Peter J Tontonoz · University Of California Los Angeles · R01 · FY2025 · DK
Lipid storage and utilization in physiology and obesity
$553,800Peter J Tontonoz · University Of California Los Angeles · R01 · FY2023 · DK
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
$553,582Yi Tan · University Of Louisville · R01 · FY2022 · HL
Fractalkine in Adipose Inflammation and Insulin Resistance
$553,483Muredach P Reilly · University Of Pennsylvania · R01 · FY2015 · DK
Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosis
$553,447David Y Hui · University Of Cincinnati · R01 · FY2024 · HL
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
$553,074Kevin Finnbar Staveleyo'carroll · University Of Missouri-Columbia · R01 · FY2021 · CA
Assessing the Influence of the Human Lipidome on Risk of Diabetes in a Minority Population
$552,650Joanne E Curran · University Of Texas Rio Grande Valley · R01 · FY2022 · DK
Glycopathology of HCC: identification of the source cells of serum fucosylation
$552,594Anand S Mehta · Medical University Of South Carolina · U01 · FY2019 · CA